Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Opioid Dependence
Interventions: Probuphine (buprenorphine implant); Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Los Angeles, California • National City, California • Jacksonville, Florida + 12 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-hRKp.RPGR; Biological
Lead sponsor: MeiraGTx Ocular UK Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Diverticulosis, Colonic
Interventions: L-glutamine; Drug
Lead sponsor: Emmaus Medical, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Torrance, California • Ventura, California • San Antonio, Texas

Conditions: Alzheimer's Disease
Interventions: MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more

Conditions: Uveitis, Posterior, Uveitis, Intermediate
Interventions: V404; Drug
Lead sponsor: Forsight Vision4; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Golden, Colorado • Atlanta, Georgia • Omaha, Nebraska + 2 more

Conditions: Hemophilia A
Interventions: Recombinant Protein-Free Factor VIII (rAHF-PFM); Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Septoplasty
Interventions: ENTACT Septal Staple system; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Boca Raton, Florida • Fort Lauderdale, Florida • Elkhart, Indiana

Conditions: Common Warts
Interventions: 10% EISO, Placebo, 20% EISO, 30% EISO; Drug
Lead sponsor: ViroXis Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Rogers, Arkansas • Fremont, California • Lomita, California + 17 more

Conditions: Cryptogenic Stroke
Interventions: Not listed
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Open Angle Glaucoma
Interventions: Streamline Surgical System, iStent Inject W; Device
Lead sponsor: New World Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 18
States / cities: Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more

Conditions: Arthroplasty, Hip Revision
Interventions: Trident II Tritanium Acetabular Shell for Revision; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Lafayette, Louisiana • New Orleans, Louisiana • Boston, Massachusetts + 7 more

Conditions: Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions: Advanced multi-component meditation practice; Behavioral
Lead sponsor: Tobias Moeller-Bertram; Industry
Eligibility: 21 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Palm Desert, California

Conditions: Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
Interventions: Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil, Therapeutic Allogeneic Lymphocytes, Laboratory Biomarker Analysis; Drug · Radiation · Procedure + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 74 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 6
States / cities: Duarte, California • Stanford, California • Denver, Colorado + 2 more

Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Sun City, Arizona • Los Angeles, California • Redwood City, California + 6 more

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 165
States / cities: Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 162 more

Conditions: Alzheimer Disease, Early Onset
Interventions: AD-35 60mg group, Placebo group; Drug
Lead sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more

Conditions: Aneurysms
Interventions: MICRUSFRAME and GALAXY coils; Device
Lead sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 30
States / cities: Tucson, Arizona • Carmichael, California • Orange, California + 26 more

Conditions: Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions: Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care; Other · Behavioral · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Moderate to Severe Pain
Interventions: Q8003, Placebo; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more

Conditions: Solid Tumors
Interventions: EC145; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Darusentan, Guanfacine, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 87
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX); Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Search by objective public record fields.

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

L-glutamine Treatment in Patients With Diverticulosis

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Safety and Performance of ENTACT Septal Staple System for Septoplasty

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

Trident II Revision Outcomes Study

Quest to Analyze One Thousand Humans Meditating

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

North American Prodromal Synucleinopathy Consortium

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms

Prediction and Prevention of Postoperative Mortality and Morbidity

Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis